ENEAPHARM
- Biotech or pharma, therapeutic R&D
Eneapharm is a clinical stage Biotech company developing EN311, a breakthrough rapid release formulation of pancreatic enzymes.
EN311 is the next-generation therapeutic candidate with the potential to transform EPI treatment.
In clinical stage (Phase FIP CTA submission on April 2025) on patients with cystic fibrosis, EN311 has already showed exceptional results in preclinical stage promising a real high efficiency in EPI treatment.
Expected potential effects: Enhanced efficacy - Fewer doses - Significantly reduced side effects.
Open to discuss opportunities.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}